Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase

Detalles: COMISIÓN DE VIH E ITS; 04 Septiembre 2023

Autores: Llibre JM, Brites C, Cheng CY, Osiyemi O, van Wyk J et al

Revista: Clin Infect Dis. 2023 Feb 18;76(4):720-729.

DOI: https://doi.org/10.1093/cid/ciac130

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase